Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 13/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17863795 | 0.90 | PIK3C3 (0.49) | PIK3C3L3MBTL1TGFBR1 | |
| SCHEMBL17840786 | 0.89 | PIK3C3 (0.38) | PIK3C3L3MBTL1MAPK14TGFBR1 | |
| SCHEMBL17840555 | 0.88 | PIK3C3 (0.38) | PIK3C3L3MBTL1MAPK14 | |
| SCHEMBL17840748 | 0.88 | PTK2 (0.40) | PIK3C3L3MBTL1MAPK14TGFBR1 | |
| SCHEMBL17840843 | 0.87 | KDR (0.39) | PIK3C3MAPK14TGFBR1 | |
| SCHEMBL25248027 | 0.85 | PIK3C3 (0.39) | PIK3C3L3MBTL1MAPK14 | |
| SCHEMBL30365755 | 0.85 | PIK3C3 (0.39) | PIK3C3L3MBTL1MAPK14 | |
| SCHEMBL17840796 | 0.85 | L3MBTL1 (0.40) | PIK3C3L3MBTL1LMNAMAPK14TGFBR1 | |
| SCHEMBL30365566 | 0.85 | L3MBTL1 (0.40) | PIK3C3L3MBTL1LMNAMAPK14TGFBR1 | |
| SCHEMBL25246220 | 0.83 | GRM5 (0.40) | PIK3C3L3MBTL1LMNAMAPK14TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4509122-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | Bayer Aktiengesellschaft (DE) | 2025-02-19 | — | — | EP | disclosed |
| EP-4188930-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | BAYER AG (DE) | 2024-10-23 | — | — | EP | disclosed |
| US-20230391769-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-12-07 | — | — | US | disclosed |
| EP-4188930-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | Bayer Aktiengesellschaft (DE) | 2023-06-07 | — | — | EP | disclosed |
| EP-3237415-A1 | TGF RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9708316-B2 | TGFβR antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708316-B2 | TGFβR antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708316-B2 | TGFβR antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| WO-2016106266-A1 | TGFβ RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016106266-A1 | TGFβ RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-30 | — | — | WO | disclosed |
| US-20160176871-A1 | TGF BETA R ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2016-06-23 | — | — | US | disclosed |
| US-20160176871-A1 | TGF BETA R ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391769-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | CYP11B2, SDHA, UGT2B7 | PIK3C3 1806/4885L3MBTL1 4701/4885LMNA 2707/4885 |
| US-20160176871-A1 | TGF BETA R ANTAGONISTS | TGFBR2, TGFBR1, TGFB1 | PIK3C3 2608/4885L3MBTL1 903/4885LMNA 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.